Canvuparatide for Hypoparathyroidism

This trial explores a new treatment called canvuparatide for individuals with hypoparathyroidism, a condition where the body produces insufficient parathyroid hormone, resulting in low calcium levels. Researchers aim to determine if weekly doses of canvuparatide are safe and effective in managing this condition. Participants will receive either the actual treatment or a placebo, an inactive substance used for comparison. The trial seeks adults who have lived with hypoparathyroidism for at least a year and currently need daily supplements of calcium and certain vitamins. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

The trial requires that your doses of calcitriol, alfacalcidol, and calcium be stable for at least 3 weeks before screening. You should not use therapies affecting calcium metabolism within 4 weeks before joining the trial.

Studies have shown that canvuparatide is generally safe for people. In one study, participants experienced no serious side effects or reasons to stop the treatment over 12 weeks. Another study found that single doses in healthy volunteers were well tolerated, with no major side effects. Longer-term research, spanning a year, also supported its safety, with most side effects being mild and no new safety concerns emerging. Overall, the treatment has demonstrated a consistent safety record, making it a promising option for those considering joining this trial.¹²³⁴⁵

Canvuparatide is unique because it offers a new approach to treating hypoparathyroidism by providing a once-weekly subcutaneous injection, which is a departure from the current need for multiple daily doses of calcium and active vitamin D supplements. This treatment acts as a drug-device combination that simplifies the administration and potentially improves adherence. Researchers are excited about canvuparatide because it may offer more consistent management of calcium levels and reduce the burden on patients compared to the current standard of care.

Research has shown that canvuparatide, which participants in this trial may receive, may help treat hypoparathyroidism (HypoPT). In one study, 63% of patients taking canvuparatide achieved the main goal, compared to only 31% of those taking a placebo, indicating better calcium levels in their blood. Another study found that 63% of patients responded well after 12 weeks, and 79% responded well after 6 months. These results suggest that canvuparatide could be an effective option for managing HypoPT.¹²³⁵⁶